Ependymoma
📧 Sign up to get email alerts when something new happens for Ependymoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors [Phase 1]
Clinical trial update indicating that Loc3CAR (B7-H3-CAR T cells) delivery is in early-phase pediatric CNS tumor trials and currently recrui…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) [Phase 2]
This update covers an ongoing Phase 2 clinical trial (INTUITT-NF2) evaluating targeted therapies for NF2-related schwannomatosis. The study …
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer [Phase 1]
A Phase 1 trial evaluating the safety of a chemo-immunotherapy combo of ibrutinib and indoximod in pediatric brain tumor patients, including…
-
CLINICAL_TRIALS trial_result · 2026-01-08Clinical Trial Update: Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG [Phase 2]
Phase 2 pediatric trial evaluating indoximod with chemotherapy and radiation for relapsed brain tumors or newly diagnosed diffuse intrinsic …
-
CLINICAL_TRIALS withdrawal · 2026-01-08Clinical Trial Update: Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies [Phase 1]
A Phase 1 trial investigating fourth-ventricular administration of nivolumab with methotrexate or 5-azacytidine for recurrent medulloblastom…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma [Phase 1]
A Phase 1 clinical trial in pediatric patients with recurrent high-grade glioma evaluating hematopoietic stem cell therapy in combination wi…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms [Phase 1]
Phase I trial update indicates ONC206 is being studied for recurrent and rare primary central nervous system neoplasms and the study is curr…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors [Phase 1]
Phase 1 trial evaluating locoregional HER2-targeted CAR T-cell therapy for pediatric recurrent or refractory central nervous system tumors a…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors [Phase 1]
Phase 1 trial evaluating locoregional EGFR806-specific CAR T cells for EGFR-positive pediatric CNS tumors. The study status is completed.
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
This clinical trial update describes an observational study by the EORTC to assess treatment patterns and outcomes for patients with primary…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma
A multicenter registry for children and young adults with intracranial localized medulloblastoma, CNS primitive neuroectodermal tumor, or ep…
-
CLINICAL_TRIALS research · 2025-11-13Clinical Trial Update: LET Optimized IMPT in Treating Pediatric Patients With Ependymoma [Phase 1]
A Phase 1 clinical trial from MD Anderson is evaluating LET-optimized intensity-modulated proton therapy (IMPT) for pediatric ependymoma and…
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer [Phase 1, Phase 2]
This document details an ongoing Phase 1/2 clinical trial evaluating cobolimab in combination with dostarlimab in pediatric and young adult …
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial [Phase 2]
This update reports on a Phase 2 pediatric MATCH trial evaluating selpercatinib for patients with activating RET gene alterations across adv…
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) [Phase 2]
Phase 2 pediatric MATCH trial evaluating larotrectinib in patients with NTRK gene fusions has posted results; the study remains active but n…
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: Pharmacoscopy for Patients With Refractory Primary Brain Tumors [Phase 2]
Phase 2 clinical trial update for pharmacoscopy in patients with refractory primary brain tumors, currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-09-02Clinical Trial Update: Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma [EARLY_Phase 1]
Early-phase study evaluating the use of 18F-FDOPA PET imaging to plan surgery and radiation therapy for adults with newly diagnosed malignan…
-
CLINICAL_TRIALS trial_result · 2025-07-30Clinical Trial Update: Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
The PEAR-GLIO trial evaluating an AI R&D tool for adult gliomas and other primary brain tumors has been terminated.
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma [Phase 1]
Phase 1 clinical trial to determine the maximum tolerated dose, safety, and tolerability of a Rhenium-186 radiopharmaceutical in pediatric p…
-
CLINICAL_TRIALS trial_result · 2025-07-08Clinical Trial Update: HUMC 1612: Optune NovoTTF-200A System [Phase 1]
Phase 1 clinical trial update for HUMC 1612 evaluating the Optune NovoTTF-200A System in high-grade glioma and ependymoma; status shows comp…
-
CLINICAL_TRIALS trial_result · 2025-06-29Clinical Trial Update: Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers [Phase 2]
A Phase 2 trial of nivolumab in patients with recurrent select rare CNS cancers (medulloblastoma, ependymoma, pineal region tumors, choroid …
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies. [EARLY_Phase 1]
An early-phase trial evaluating TP53 cDNA gene therapy combined with checkpoint inhibition and radiation in children with recurrent or refra…
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation [Phase 2]
Phase 2 clinical trial evaluating proton radiotherapy for pediatric brain tumors requiring partial brain irradiation has completed enrollmen…
-
CLINICAL_TRIALS research · 2025-05-29Clinical Trial Update: Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents
Clinical trial update describing a multiomic study on radioresistance in pediatric ependymomas; recruitment is ongoing.
-
CLINICAL_TRIALS trial_result · 2025-04-22Clinical Trial Update: Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors [Phase 2]
Phase 2 trial of selumetinib in Neurofibromatosis type II–related tumors was terminated, with results posted in 2025; the study included ves…